10x Genomics, Inc. (NASDAQ:TXG) Poised For Near-Term Mean Reversion Despite Bearish Momentum

10x Genomics shows mixed signals: strong cash and margin fundamentals contrast with weakening technical momentum, creating a short-term environment where mean-reversion trades could appear. WMDST values the stock as under-valued.

Recent News

On August 7, 2025 the company scheduled its second-quarter 2025 results release after market close and announced an acquisition to expand single‑cell scale capabilities; the acquisition aims to enhance the Chromium platform and broaden access to high‑throughput single‑cell analysis. In late July 2025 the stock received a Relative Strength rating upgrade from market data services, reflecting improved price performance over the prior 52 weeks. Additional announcements in August referenced strategic purchases to extend in‑situ and spatial sequencing capabilities.

Technical Analysis

Directional indicators present bearish pressure: DI+ declines while DI- shows a dip-and-reversal that counts as bearish, and ADX at 19.61 classifies trend strength as absent. Collectively, directional signals favor downward pressure rather than a trending breakout.

MACD registers -0.25 and trends downward with the MACD line below its signal at -0.08, a bearish momentum profile that fails to show a bullish crossover required for momentum confirmation.

MRO stands at -32.88 and trends lower; the oscillator’s negative reading indicates price sits below the modeled target, which commonly precedes corrective upward movement toward that target rather than continued extension below valuation.

RSI at 50.19 on a decreasing trend suggests neutral-to-soft momentum with room for either a pullback or a recovery; the reading does not signal an extreme condition but aligns with declining short-term strength.

Price sits beneath the 20‑day average ($12.76), 50‑day average ($13.24), and slightly below the 200‑day average ($11.84). The 12‑day EMA ($12.61) and 26‑day EMA ($12.93) both trend downward, reinforcing short‑term price weakness while the close ($11.72) trades below the lower 1x Bollinger band ($12.15), indicating compressed volatility with a price below recent statistical support.

Volatility measures present elevated beta readings—42‑day beta 2.74 and 52‑week beta 1.94—so any directional move will likely produce amplified price swings. Average volume sits near 2.53M over 10 days versus a 200‑day average near 3.16M, showing slightly lighter recent participation versus long‑term average.

 


Fundamental Analysis

Revenue displayed notable growth: year‑over‑year revenue growth stands at 35.64% while quarter‑over‑quarter revenue movement reads -289.45%. The YoY increase reflects expanding end‑market adoption; the QoQ decline reflects seasonal or timing effects in the quarter reported.

Profitability metrics present mixed strength. EBIT totals $37,000,000 and translates to an EBIT margin of 21.40%, slightly above the industry peer mean of 19.00% and industry peer median of 19.467%. Operating margin registers -6.115% and compares against the industry peer mean of 16.981%; the gap stems from non‑operating gains and expense timing differences that lift EBIT relative to operating income.

Cash and liquidity metrics show robust coverage: cash at $397,712,000 and cash plus short‑term investments at $447,261,000 support a current ratio of 584.26% and a quick ratio of 522.80%, indicating substantial short‑term liquidity versus current liabilities. The cash conversion cycle at 135.65 days sits near the industry peer mean of 132.44 days.

Return metrics remain modest: return on equity at 4.466% and return on assets at 3.668% reflect early‑stage capital deployment and investment in R&D ($61,224,000). Gross margin at 72.341% provides strong product-level profitability and supports operating leverage as revenue scales.

Valuation multiples present a varied picture: P/E at 41.92x, P/S at 9.00x, and price‑to‑book at 2.01x. Free cash flow yield equals 1.04% while enterprise multiple registers 25.64x. WMDST values the stock as under‑valued based on the firm’s free cash dynamics, cash position, and margin profile despite elevated multiples on revenue‑adjusted metrics.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-07
NEXT REPORT DATE: 2025-11-06
CASH FLOW  Begin Period Cash Flow 377.1 M
 Operating Cash Flow 17.7 M
 Capital Expenditures -1.58 M
 Change In Working Capital -53.69 M
 Dividends Paid
 Cash Flow Delta 20.7 M
 End Period Cash Flow 397.7 M
 
INCOME STATEMENT REVENUE
 Total Revenue 172.9 M
 Forward Revenue -47.50 M
COSTS
 Cost Of Revenue 47.8 M
 Depreciation 9.7 M
 Depreciation and Amortization 9.7 M
 Research and Development 61.2 M
 Total Operating Expenses 183.5 M
PROFITABILITY
 Gross Profit 125.1 M
 EBITDA 46.7 M
 EBIT 37.0 M
 Operating Income -10.57 M
 Interest Income 4.3 M
 Interest Expense 3.0 K
 Net Interest Income 4.3 M
 Income Before Tax 37.0 M
 Tax Provision 2.5 M
 Tax Rate 6.646 %
 Net Income 34.5 M
 Net Income From Continuing Operations 34.5 M
EARNINGS
 EPS Estimate -0.08
 EPS Actual 0.48
 EPS Difference 0.56
 EPS Surprise 700.0 %
 Forward EPS -0.30
 
BALANCE SHEET ASSETS
 Total Assets 980.0 M
 Intangible Assets 19.2 M
 Net Tangible Assets 754.1 M
 Total Current Assets 655.7 M
 Cash and Short-Term Investments 447.3 M
 Cash 397.7 M
 Net Receivables 50.0 M
 Inventory 69.0 M
 Long-Term Investments 2.7 M
LIABILITIES
 Accounts Payable 15.9 M
 Short-Term Debt
 Total Current Liabilities 112.2 M
 Net Debt
 Total Debt 86.7 M
 Total Liabilities 206.7 M
EQUITY
 Total Equity 773.3 M
 Retained Earnings -1.47 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 6.21
 Shares Outstanding 124.442 M
 Revenue Per-Share 1.39
VALUATION
 Market Capitalization 1.6 B
 Enterprise Value 1.2 B
 Enterprise Multiple 25.64
Enterprise Multiple QoQ -169.52 %
Enterprise Multiple YoY -129.415 %
Enterprise Multiple IPRWA high: 142.585
median: 72.241
mean: 71.869
TXG: 25.64
low: -148.838
 EV/R 6.918
CAPITAL STRUCTURE
 Asset To Equity 1.267
 Asset To Liability 4.741
 Debt To Capital 0.101
 Debt To Assets 0.089
Debt To Assets QoQ -0.135 %
Debt To Assets YoY 280.241 %
Debt To Assets IPRWA high: 0.847
median: 0.348
mean: 0.327
TXG: 0.089
low: 0.051
 Debt To Equity 0.112
Debt To Equity QoQ -0.971 %
Debt To Equity YoY 275.309 %
Debt To Equity IPRWA high: 3.117
median: 0.697
mean: 0.675
TXG: 0.112
low: 0.067
PRICE-BASED VALUATION
 Price To Book (P/B) 2.013
Price To Book QoQ 16.581 %
Price To Book YoY -44.795 %
Price To Book IPRWA high: 8.583
mean: 4.052
median: 3.432
TXG: 2.013
low: 0.246
 Price To Earnings (P/E) 41.919
Price To Earnings QoQ -218.404 %
Price To Earnings YoY -161.207 %
Price To Earnings IPRWA high: 111.763
mean: 80.748
median: 79.394
TXG: 41.919
low: -75.925
 PE/G Ratio -0.21
 Price To Sales (P/S) 9.003
Price To Sales QoQ 14.235 %
Price To Sales YoY -47.795 %
Price To Sales IPRWA high: 37.916
mean: 17.239
median: 15.972
TXG: 9.003
low: 0.528
FORWARD MULTIPLES
Forward P/E -32.843
Forward PE/G 0.164
Forward P/S -32.769
EFFICIENCY OPERATIONAL
 Operating Leverage -18.081
ASSET & SALES
 Asset Turnover Ratio 0.184
Asset Turnover Ratio QoQ 8.005 %
Asset Turnover Ratio YoY 11.09 %
Asset Turnover Ratio IPRWA TXG: 0.184
high: 0.173
mean: 0.118
median: 0.108
low: 0.038
 Receivables Turnover 3.373
Receivables Turnover Ratio QoQ 52.89 %
Receivables Turnover Ratio YoY 101.01 %
Receivables Turnover Ratio IPRWA TXG: 3.373
high: 2.963
mean: 1.346
median: 1.273
low: 0.962
 Inventory Turnover 0.666
Inventory Turnover Ratio QoQ 6.255 %
Inventory Turnover Ratio YoY 16.748 %
Inventory Turnover Ratio IPRWA high: 2.37
median: 1.196
mean: 1.033
TXG: 0.666
low: 0.187
 Days Sales Outstanding (DSO) 27.053
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 135.65
Cash Conversion Cycle Days QoQ -12.569 %
Cash Conversion Cycle Days YoY -23.667 %
Cash Conversion Cycle Days IPRWA high: 448.101
TXG: 135.65
mean: 132.437
median: 107.055
low: 51.486
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.318
 CapEx To Revenue -0.009
 CapEx To Depreciation -0.164
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 773.3 M
 Net Invested Capital 773.3 M
 Invested Capital 773.3 M
 Net Tangible Assets 754.1 M
 Net Working Capital 543.4 M
LIQUIDITY
 Cash Ratio 3.986
 Current Ratio 5.843
Current Ratio QoQ 8.743 %
Current Ratio YoY 11.997 %
Current Ratio IPRWA high: 12.395
TXG: 5.843
mean: 2.221
median: 1.933
low: 0.756
 Quick Ratio 5.228
Quick Ratio QoQ 11.699 %
Quick Ratio YoY 18.238 %
Quick Ratio IPRWA high: 7.325
TXG: 5.228
mean: 1.707
median: 1.496
low: 0.701
COVERAGE & LEVERAGE
 Debt To EBITDA 1.859
 Cost Of Debt 0.0 %
 Interest Coverage Ratio 12333.333
Interest Coverage Ratio QoQ -173.619 %
Interest Coverage Ratio YoY -133.263 %
Interest Coverage Ratio IPRWA TXG: 12333.333
high: 33.857
mean: 7.21
median: 5.23
low: -23.105
 Operating Cash Flow Ratio 0.52
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 24.0
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 8.477 %
 Revenue Growth 11.638 %
Revenue Growth QoQ -289.451 %
Revenue Growth YoY 35.641 %
Revenue Growth IPRWA high: 16.567 %
TXG: 11.638 %
mean: 4.913 %
median: 4.728 %
low: -0.773 %
 Earnings Growth -200.0 %
Earnings Growth QoQ 566.667 %
Earnings Growth YoY 455.556 %
Earnings Growth IPRWA high: 71.304 %
mean: 5.931 %
median: 4.078 %
low: -61.905 %
TXG: -200.0 %
MARGINS
 Gross Margin 72.341 %
Gross Margin QoQ 6.259 %
Gross Margin YoY 6.273 %
Gross Margin IPRWA high: 89.231 %
TXG: 72.341 %
mean: 46.375 %
median: 40.612 %
low: 3.787 %
 EBIT Margin 21.399 %
EBIT Margin QoQ -198.918 %
EBIT Margin YoY -188.36 %
EBIT Margin IPRWA high: 65.47 %
TXG: 21.399 %
median: 19.467 %
mean: 19.002 %
low: -167.282 %
 Return On Sales (ROS) -6.115 %
Return On Sales QoQ -71.733 %
Return On Sales YoY -74.75 %
Return On Sales IPRWA high: 40.537 %
median: 17.652 %
mean: 16.981 %
TXG: -6.115 %
low: -167.282 %
CASH FLOW
 Free Cash Flow (FCF) 16.1 M
 Free Cash Flow Yield 1.036 %
Free Cash Flow Yield QoQ -61.038 %
Free Cash Flow Yield YoY 656.204 %
Free Cash Flow Yield IPRWA high: 13.177 %
TXG: 1.036 %
median: 0.637 %
mean: 0.589 %
low: -16.613 %
 Free Cash Growth -50.305 %
Free Cash Growth QoQ -88.644 %
Free Cash Growth YoY -57.874 %
Free Cash Growth IPRWA high: 206.094 %
median: 206.094 %
mean: 120.763 %
TXG: -50.305 %
low: -222.423 %
 Free Cash To Net Income 0.467
 Cash Flow Margin 33.76 %
 Cash Flow To Earnings 1.69
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 3.668 %
Return On Assets QoQ -197.269 %
Return On Assets YoY -189.66 %
Return On Assets IPRWA high: 3.831 %
TXG: 3.668 %
mean: 1.71 %
median: 1.615 %
low: -14.729 %
 Return On Capital Employed (ROCE) 4.264 %
 Return On Equity (ROE) 0.045
Return On Equity QoQ -191.893 %
Return On Equity YoY -185.327 %
Return On Equity IPRWA high: 0.104
TXG: 0.045
mean: 0.035
median: 0.032
low: -0.217
 DuPont ROE 4.667 %
 Return On Invested Capital (ROIC) 4.467 %
Return On Invested Capital QoQ -219.279 %
Return On Invested Capital YoY -45.338 %
Return On Invested Capital IPRWA high: 5.983 %
TXG: 4.467 %
mean: 2.407 %
median: 2.332 %
low: -17.594 %

Six-Week Outlook

Near term, technical momentum tilts bearish until MACD reverses above its signal or DI+ halts its decline; ADX below 20 implies any directional conviction remains weak. Price trades below short‑ and medium‑term moving averages and under the 1x Bollinger band, so expect volatility that can produce mean‑reversion rallies back toward the 20‑day and 50‑day averages when momentum indicators register a bullish flip.

MRO’s negative reading signals price beneath the modeled target, which often precedes corrective upward moves rather than extended declines; however the current MACD and falling EMA values increase the probability of rangebound action with volatility spikes. Watch for a MACD cross above its signal and stabilization of DI+ as objective confirmation for momentum to shift; absent that, expect the stock to remain vulnerable to renewed selling pressure from a failing momentum context.

About 10x Genomics, Inc.

10x Genomics, Inc. (NASDAQ:TXG) develops and markets advanced life science technologies that enable comprehensive analysis of biological systems. The company offers a range of products, including instruments, consumables, and software, to facilitate detailed biological research. 10x Genomics designs the Chromium series of instruments, which support single cell solutions for gene expression analysis, immune profiling, and epigenetic studies. These solutions allow researchers to examine gene activity and networks on an individual cell basis, providing insights into cellular functions and interactions. In addition to its single cell technologies, 10x Genomics provides the Visium platform, which allows researchers to explore spatial relationships of biological components within tissues. The Xenium platform further enhances research capabilities with in situ analysis, offering high-resolution insights into molecular biology. Serving a diverse clientele, including academic institutions, government entities, and biopharmaceutical companies, 10x Genomics supports cutting-edge research worldwide. Headquartered in Pleasanton, California, the company continues to expand its impact across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. Founded in 2012, 10x Genomics remains a key player in advancing biological research technologies.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.